Bcl-xL expression in tumors antagonizes the therapeutic efficiency of ERBB2 downregulation. Bcl-xL expression in tumors antagonizes the therapeutic efficiency.

Slides:

Advertisements

Similar presentations

Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V A B C ANXA1.

Advertisements

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.

Inhibition of β-catenin by the Smad4/BMP pathway.

eIF5A-PEAK1 signaling regulates KRAS protein expression.

Src acetylation is critical for its tumorogenesis property.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Effects of knockdown of DDR1 levels on proliferation and apoptosis.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

coTCRcys-transduced T cells control tumor growth in vivo.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

Protein expression profile in a dasatinib-resistant cell line.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

Heat map of genes for which CR significantly altered expression versus AL. Cluster analysis of genes significantly changed by the CR intervention compared.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Matriptase-2 inhibited breast tumor development in vivo.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Vascular staining in CWR22R xenograft tumors.

Overexpression of L1 in CRC cells induces NF-κB activation and suppression of p65 expression blocks the capacity to confer liver metastasis. Overexpression.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Active AR signaling in enzalutamide-resistant xenograft tumors.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

Overexpression of EP4 with cAMP-PKA signal activation promoted the castration-resistant progression of LNCaP cells through AR activation. Overexpression.

FOXO-responsive 3X-IRS promoter activity is reduced in LNAI cells versus LNCaP cells. FOXO-responsive 3X-IRS promoter activity is reduced in LNAI cells.

Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. LNCaP,

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Induction of apoptosis in mismatch repair-deficient tumor cell lines after microinjection of phMSH2 and phMLH1 cDNA expression constructs. Induction of.

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

Gene expression levels of ESR1 (A), ERBB2 (B), MiK67(C), and PCNA (D) in pre- and postneoadjuvant chemotherapy samples (n = 21). Gene expression levels.

Isolation of stable XPAKD and XPCKD HeLa clones.

Mean cell number in small intestinal crypt (a), small intestinal villus (b), and midcolonic crypt (c) of BALB/c (♦) and DBA/2 (▪) mice after two injections.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Whole-mount analysis of tumor induced lymphatic sprouting by confocal microscopy. Whole-mount analysis of tumor induced lymphatic sprouting by confocal.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Effect of dietary feeding of silibinin on DU145 tumor xenograft growth in athymic male nude mice. Effect of dietary feeding of silibinin on DU145 tumor.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

PVT1 facilitated gastric cancer progression in a FOXM1-mediated manner

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

The CCR5+ population of SUM-159 cells is enriched with tumor-initiating cells. The CCR5+ population of SUM-159 cells is enriched with tumor-initiating.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

Biodistributions 24 hours after injection of different 177Lu-chCE7F(ab′)2 conjugates ( MBq, 13 μg) in tumor-bearing nude mice: effect of the number.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Decreased dopamine uptake following downregulation of SLC6A3.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

IL-1β expression is increased in MM cell lines by the co-culture with platelets in vitro. IL-1β expression is increased in MM cell lines by the co-culture.

A. A. Comparison of transient HSAKIN17 gene silencing induced by either siRNA duplexes or EBV-based siRNA vectors. Twenty-four hours after seeding, HeLa.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

T cells expressing a KIR-CAR/Dap12 show potent in vivo antitumor activity that is resistant to the tumor-induced T-cell hypofunction observed with CD3ζ-based.

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Presentation transcript:

Bcl-xL expression in tumors antagonizes the therapeutic efficiency of ERBB2 downregulation. Bcl-xL expression in tumors antagonizes the therapeutic efficiency of ERBB2 downregulation. Subcutaneous tumors were induced in nude mice by injection of NIH3T3 cells expressing ERBB2, ERBB2 and Bcl-xL, as well as cells expressing ERBB2 mock-transfected with an empty vector. Downregulation of ERBB2 was achieved by daily injections of anhydrotetracycline for 7 d. The alteration of tumor volume compared with the day of the first anhydrotetracycline injection (day 0) is given. A, NIH3T3 cells expressing ERBB2 and Bcl-xL (Bcl-xL) versus NIH3T3 cells expressing ERBB2 and mock-transfected with an empty vector (MOCK). B, NIH3T3 cells expressing ERBB2 and Bcl-xL (Bcl-xL) versus NIH3T3 cells expressing ERBB2 (ERBB2). C, NIH3T3 cells expressing ERBB2 and mock-transfected with an empty vector (MOCK) versus NIH3T3 cells expressing ERBB2 (ERBB2). Comparing mock-transfected cells to the parental NIH3T3-ERBB2 cells showed that the retroviral transduction itself might have induced a slight increase in resistance (C). However, this small difference cannot explain the much larger effect observed in the presence of Bcl-xL (A and B). Ilka Brigitte Petry et al. Clin Cancer Res 2010;16:451-460 ©2010 by American Association for Cancer Research